The present work reports for the first time that the gene MAP1A could be a potential biomarker in the early diagnosis, prognosis, and immunotherapy of low-grade bladder cancer (non-muscle invasion and superficial muscle invasion stages). Here, MAP1A is linked to urinary bladder carcinoma.